The detection of neural antibodies in patients with paraneoplastic and autoimmune encephalitis has majorly advanced the diagnosis and management of neural antibody-associated diseases. Although testing for these antibodies has historically been restricted to specialized centers, assay commercialization has made this testing available to clinical chemistry laboratories worldwide. This improved test accessibility has led to reduced turnaround time and expedited diagnosis, which are beneficial to patient care. However, as the utilization of these assays has increased, so too has the need to evaluate how they perform in the clinical setting. In this chapter, we discuss assays for neural antibody detection that are in routine use, draw attention to their limitations and provide strategies to help clinicians and laboratorians overcome them, all with the aim of optimizing neural antibody testing for paraneoplastic and autoimmune encephalitis in clinical practice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/B978-0-12-823912-4.00002-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biomarkers.
Alzheimers Dement
December 2024
University of Massachusetts Medical School, Worcester, MA, USA.
Background: Neuron-derived extracellular vesicles (NDEVs) are a valuable resource for understanding brain conditions and discovering neurodegenerative diseases biomarkers, notably Alzheimer's disease (AD). Recent interest focuses on capturing neuron-specific EVs from patient-derived samples, characterizing their contents as a pathological reflection of the central nervous system (CNS). Our recent study identified ATPase Na/K Transporting Subunit Alpha 3 (ATP1A3) as a prevalent neuron-specific EV marker specifically expressed in brains.
View Article and Find Full Text PDFBackground: Hallmark features of AD are well defined, however, the generation of in vitro models of sporadic AD poses a significant challenge due to the complex, undefined etiology and slow progression of this disease. Herpes simplex virus type I (HSV-1) is a pathogen that is gaining increasing attention as a potential causative agent in AD pathogenesis. HSV-1 is a DNA virus that typically resides throughout the peripheral nervous system in a latent state.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Background: Analysis of neuroimaging data based on convolutional neural networks (CNNs) can improve detection of clinically relevant characteristics of patients with Alzheimer's disease (AD). Previously, our group developed a CNN-based approach for detecting AD via magnetic resonance imaging (MRI) scans and for identifying features that are relevant to the decision of the network. In the current study, we aimed to evaluate the potential utility of applying this approach to MRI scans to assist in the identification of individuals at high risk for amyloid positivity to aid in the selection of study samples and case finding for treatment.
View Article and Find Full Text PDFAlzheimer's Imaging Consortium.
Alzheimers Dement
December 2024
German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Background: Analysis of neuroimaging data based on convolutional neural networks (CNNs) can improve detection of clinically relevant characteristics of patients with Alzheimer's disease (AD). Previously, our group developed a CNN-based approach for detecting AD via magnetic resonance imaging (MRI) scans and for identifying features that are relevant to the decision of the network. In the current study, we aimed to evaluate the potential utility of applying this approach to MRI scans to assist in the identification of individuals at high risk for amyloid positivity to aid in the selection of study samples and case finding for treatment.
View Article and Find Full Text PDFImplementation of machine learning tool for continued process verification of process chromatography unit operation.
J Chromatogr A
December 2024
Department of Chemical Engineering, Indian Institute of Technology Delhi, New Delhi, India. Electronic address:
Recent advancements in technology, such as the emergence of artificial intelligence (AI) and machine learning (ML), have facilitated the progression of the biopharmaceutical industry toward the implementation of Industry 4.0. As per the guidelines set by the USFDA, process validation for biopharmaceutical production consists of three stages: process design, process qualification, and continuous process verification (CPV).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!